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Abstract
A mysterious disease affecting calves, named bovine neonatal pancytopenia (BNP), emerged in 2007 in several
European countries. Epidemiological studies revealed a connection between BNP and vaccination with an
inactivated vaccine against bovine virus diarrhea (BVD). Alloantibodies reacting with blood leukocytes of calves
were detected in serum and colostrum of dams, which have given birth to calves affected by BNP. To understand
the linkage between vaccination and the development of alloantibodies, we determined the antigens reacting
with these alloantibodies. Immunoprecipitation of surface proteins from bovine leukocytes and kidney cells using
sera from dams with a confirmed case of BNP in their gestation history reacted with two dominant protein species
of 44 and 12 kDa. These proteins were not detected by sera from dams, free of BVDV and not vaccinated against
BVD, and from sera of animals vaccinated with a different inactivated BVD vaccine. The 44 kDa protein was
identified by mass spectrometry analysis as MHC I, the other as b-2-microglobulin. The presence of major
histocompatibility complex class I (MHC I) in the vaccine was confirmed by Western blot using a MHC I specific
monoclonal antibody. A model of BNP pathogenesis is proposed.
Introduction
A mysterious hemorrhagic disease of cattle emerged in
2007 affecting solely newborn calves [1]. First named
“blood sweating”, “hemorrhagic diathesis” and “bleeding
calf syndrome” it was finally designated “bovine neonatal
pancytopenia” (BNP) at the Satellite Symposium of the
European Buiatric Congress in 2009 [2]. During the last
years an increasing number of calves were affected by
this syndrome. BNP cases were reported for several
breeds and both genders are affected equally. Reports of
BNP affected calves are known from several European
countries including France, Germany, United Kingdom,
Ireland, Netherlands, Belgium, Luxembourg, Italy, and
Spain [2,3]. The disease is unknown in countries which
do not vaccinate against bovine virus diarrhea virus
(BVDV) like Denmark, Austria, and Switzerland [4].
BNP is characterized by severe external and internal
hemorrhages. Clinical studies have shown that the bleed-
ings are caused by a massive thrombocytopenia, usually
connected with a severe leukopenia and depletion of
bone marrow cells, the latter may result in complete
aplasia [1,5-7]. Mortality is up to 90% in affected calves;
mild to subclinical manifestations are rarely observed [8].
In the past, bleeding disorders in cattle due to thrombo-
cytopenia have been described primarily as a consequence
of intoxications and viral infections, but sporadic cases
were also linked to bacterial septicemia, hereditary diseases
or immune mediated processes [9]. Several hypotheses
have been put forward with regard to the etiology of BNP,
such as bacterial and virus infections (BVDV, bluetongue
virus, porcine circovirus 2 [9]) or intoxications but could
not be confirmed [1,8,10]. A genetic etiology of BNP was
discussed, but BNP appearance showed no link to certain
genotypes. Epidemiological studies showed that mutations
in coagulation factor XI [11] or certain MHC class II haplo-
types [12] were not associated with BNP outbreaks. In BNP
affected calves, the often dramatic decline of thrombocyte
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and leukocyte counts within the first hours after ingestion
of colostrum, together with the characteristic bone marrow
findings (panmyelophthisis, phagocytic bone marrow
macrophages) led to the assumption of an immune
mediated process [13,14].
The occurrence of BNP is correlated with vaccination
with an inactivated bovine virus diarrhea virus (BVDV) vac-
cine termed PregSure® BVD (Pfizer, Karlsruhe, Germany)
[4]. The vaccine contains cytopathogenic BVDV type 1
(strain 5960) grown on a bovine kidney cell line and as
adjuvant Quil A, cholesterol, amphigen base and liquid
paraffin (Procision-A™) [15]. Quil A is a mixture of sapo-
nins, which are extracted from the bark of the tree Quillaja
saponaria Molina. Quil A forms immune-stimulatory com-
plexes (ISCOMS) together with the other components of
the adjuvant and antigens [16,17]. ISCOMS efficiently
induce both, antigen-specific antibodies (IgG1 and IgG2) as
well as T-cell response (Th1 and Th2) [18,19]. PregSure®
BVD was introduced in 2005. After growing evidence for a
connection between the use of the vaccine and the occur-
rence of BNP the vaccine was retracted from the market by
the manufacturer in 2010. It was speculated that vaccina-
tion with PregSure® BVD induces alloantibodies which are
transmitted via colostrum to the calves. According to this
model antigens of the vaccine elicit antibodies that bind to
peripheral blood cells as well as to the stem cells in the
bone marrow of neonates, which elevated cytophagocytosis
of opsonised cells by bovine macrophages [14,20].
Friedrich et al. demonstrated that BNP can be repro-
duced in healthy calves by transmission of colostrum from
dams, which have given birth to at least one calf with con-
firmed BNP [4]. Alloantibodies (also called isoantibodies)
were found in colostrum and serum of BNP-dams with
exhibited reactivity with leukocytes from susceptible calves
[20-22]. According to our definition BNP-dams are ani-
mals, which have a common vaccination history with
PregSure® BVD and have given birth to at least one calf
with confirmed BNP syndrome. Non-BNP-dams are ani-
mals which were also vaccinated with PregSure® BVD, but
in their gestation history no case of BNP appeared. Sus-
ceptible calves are defined as newborns whose leukocytes
bind alloantibodies from BNP-dam sera [21,22].
In Europe, over 4000 confirmed BNP cases were
reported [20]. This reveals, in relation to 13 million sold
doses of PregSure® BVD in Europe [23] that the number
of vaccinated dams with healthy offspring (non-BNP-
dams) exceeds by far the number of dams whose offspring
is affected by BNP. Apart from blood-group specific anti-
gens an induction of alloantibodies has not yet been docu-
mented for a vaccine, so far [24-26].
Elucidation of BNP pathogenesis requires the identifi-
cation of antigen(s) targeted by the alloantibodies. Here
we report on the identification of MHC I as antigen
specifically reacting with sera from BNP-dams.
Materials and methods
MDBK cells and primary bovine leukocytes
Madin-Darby bovine kidney cells (ATCC-CCL22) were
grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal calf serum
(FCS). The cells were maintained at 37°C and 5% CO2
for propagation.
Isolation of leukocytes was performed as described
before [21]. Briefly, 50 mL of freshly collected blood
samples were centrifuged (5 min with 2000 × g), the
buffy coat was collected and washed with PBS. Contami-
nating erythrocytes were lysed by an incubation for
5 min in 5 mL lysis buffer (155 mM NH4Cl, 10 mM
KHCO3, 0.13 mM EDTA) and the remaining leukocytes
were harvested by centrifugation (5 min with 2000 × g).
For quality control, the obtained leukocytes were
counted and membrane integrity was assessed using try-
pan blue staining.
Animals and serum samples
For serum preparation, peripheral blood samples were
obtained from bovines at the Clinic for Ruminants,
Justus-Liebig-University, Giessen. Different groups of
blood donors were selected: BNP-dam sera (Group 1,
n = 12) originated from dams, which had at least
received a primary vaccination (two injections) with
PregSure® BVD and had given birth to at least one
confirmed BNP-calf. For this study we considered
“confirmed BNP-calves” as animals that (i) received
colostrum only from their own dam, (ii) developed
clinical signs of BNP, and (iii) showed severe thrombo-
cytopenia and leukopenia, together with (iiii) depletion
of the bone marrow.
A second group of serum samples originated from
animals vaccinated with a different inactivated BVDV
vaccine (Bovilis® BVD, Intervet, Boxmeer, The Nether-
lands) (Group 2, n = 8), which were kindly provided by
the Institute for Hygiene and Infectious Diseases of Ani-
mals, Justus-Liebig-University, Giessen. A third group of
serum donors came from two farms with a BVDV free
status. These dams were not vaccinated against BVD
(Group 3, n = 8) and had no neutralizing antibodies
against BVDV.
Additional blood samples were collected from Preg-
Sure® BVD vaccinated animals from two farms, that had
no reported case of BNP in their gestation history (non-
BNP-dams) (Group 4, n = 4).
Sodium citrate was added in a proportion of 1:10 to
the blood samples to prevent coagulation during retrie-
val. For serum production the anticoagulation effect of
citrate was reversed by the addition of calcium chloride
in a proportion of 1:300. Coagulation was allowed for 12
h at room temperature and blood samples were centri-
fuged (20 min at 2500 × g) to obtain the serum.
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Monoclonal antibodies and reagents
For the detection of cattle MHC class I the mouse mono-
clonal antibody IL-A88 was employed [27]. Streptavidin-
HRP-conjugate, HRP-coupled goat anti-mouse antibodies
were purchased from Dianova (Hamburg, Germany).
Protein isolation from the PregSure® BVD vaccine
The total protein content of 1 mL PregSure® BVD vac-
cine was prepared by acetone precipitation. Briefly,
1 mL of the vaccine and 4 mL of ice cold acetone were
mixed and incubated for two hours on ice. After centri-
fugation, the protein pellet was washed with n-hexane
and ether to gain the vaccines proteome extricated from
lipid contamination.
Labelling of cell surface proteins and
immunoprecipitation
Cell surface proteins of 2 × 106 MDBK cells or 2 × 106
bovine leukocytes were labelled with thiol cleavable EZ-
Link Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific,
Rockford, IL, USA) according to manufacturer’s recom-
mendation. Briefly, the cells were washed with phosphate
buffered saline (PBS) and labelling was performed for
30 min at 4°C. The labelling medium was then removed,
biotinylation was stopped by incubation with 100 mM gly-
cine and cells were washed and resuspended in 1 mL PBS.
300 μL of the respective undiluted bovine serum were
added to each cell preparation and incubated for 90 min
at 4°C on an agitator. Afterwards the cells were washed
with PBS to eliminate unbound serum antibodies. Cells
were lysed in 1 mL Triton X-100 buffer (1% Triton X-100,
150 mM NaCl, 50 mM Tris-HCl, 5 mM EDTA) in an
ultrasonic bath at 4°C for 10 min. Insoluble matter was
removed by centrifugation at 10 000 × g for 10 min at 4°C.
Bovine antibodies together with the bound cellular pro-
teins were isolated from these lysate with 35 μL protein-
G-sepharose bead slurry (GE Healthcare, Munich,
Germany). After an incubation of 90 min at 4°C on an agi-
tator, the sepharose was washed four times with 1.5 mL
ice cold lysis buffer. Proteins were harvested in 25 μL of
loading buffer (6 M urea, 62.5 mM Tris-HCl, 2% SDS,
10% glycerol, 0.025% bromophenol blue, 0.025% phenol
red) and resolved by SDS-PAGE. To prevent cleavage of
the biotin linker all gels were run under non-reducing
conditions and visualized by Western blotting and strepta-
vidin-peroxidase.
SDS-PAGE and Western blotting analysis
Proteins were separated in 7.5% polyacrylamide-tricin gel
systems [28]. After SDS-PAGE, proteins were transferred
to a nitrocellulose membrane (Pall Corporation, Dreieich,
Germany). The membrane was blocked with 10% (w/v)
Roti Block (Carl Roth, Karlsruhe, Germany) in PBS with
0.1% Tween 20 (v/v). After incubation with primary anti-
bodies, HRP-conjugated goat anti-mouse IgG was added.
For biotinylated proteins, streptavidin-peroxidase concen-
trate was used in a dilution of 1:30.000. A chemilumines-
cence reagent (Western Lightning Plus, Perkin Elmer,
Rodgau, Germany) and X-ray films were utilized for signal
detection.
PNGase F digestion for detection of protein glycosylation
BNP-dam sera immunoprecipitated MDBK lysate (5 μL)
was mixed with 5 μL of G7 reaction buffer and NP40
from a PNGase F kit (New England Biolabs, Ipswich,
MA, USA). PNGase F (5 μL) was added and incubation
carried out for 2 h at 37°C. 7.5 μL of loading buffer
were added, the preparation was heated up for 5 min at
95°C, resolved by SDS-PAGE and visualized by Western
blotting and streptavidin-peroxidase.
Identification of target antigens of BNP-dam sera
alloantibodies by peptide mass fingerprinting
For quantitative preparation of target antigens an
upscaled immunoprecipitation was performed essentially
as described above. For this purpose, 3 × 107 biotinylated
MDBK cells were incubated with 3 mL of serum (in a
total of 10 mL PBS) for 90 min at 4°C. Unbound antibo-
dies were removed by repeated washes with PBS and
cells were lysed in Triton X-100 buffer. Bovine IgG along
with the target antigens was purified with 100 μL pro-
tein-G-sepharose bead slurry. Proteins were separated by
SDS-PAGE and stained using coomassie brilliant blue
G-250 (1% coomassie G-250 (w/v), 40% methanol (v/v),
and 10% acetic acid (v/v)). The bands of interest (44 kDa
and 12 kDa) were excised. After reduction with dithio-
threitol (DTT) and carbamidomethylation, proteins were
digested with trypsin. Matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-
TOF-MS) was performed on an Ultraflex I TOF/TOF
mass spectrometer (Bruker Daltonics, Bremen, Germany)
equipped with a nitrogen laser and a LIFT-MS/MS facil-
ity. The instrument was operated in the positive-ion
reflectron mode using 2,5-dihydroxybenzoic acid and
methylendiphosphonic acid (both from Sigma-Aldrich,
St.Louis, MO, USA) as matrix. Sum spectra consisting of
200-400 single spectra were acquired. For data processing
and instrument control the Compass 1.1 software pack-
age consisting of FlexControl 2.4, FlexAnalysis 3.0 and
BioTools 3.0 was used.
Proteins were identified by MASCOT peptide mass
fingerprint search using the NCBInr database. The
search was restricted to bovine proteins, a mass toler-
ance of 75 ppm was allowed and carbamidomethylation
of cysteine as global modification and oxidation of
methionine as variable modification were used.
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Results
Precipitation of cell surface antigens from MDBK cells
with BNP-dam sera
It has recently been described that BNP alloantibodies
react with intact leukocytes of susceptible calves [20-22].
We therefore selectively labelled cell surface proteins
with a membrane impermeable biotinylation reagent and
incubated with sera of different dams. After incubation,
washing and lysis of the cells antibodies bound to anti-
gens on the cells were affinity purified using protein-G-
sepharose. Antigen was eluted with a buffer containing
2% SDS and 6 M urea, subjected to SDS-PAGE and
transferred to nitrocellulose. Signals of biotinylated pro-
teins were revealed using HRP conjugated streptavidin.
It appeared likely that the induction of alloantibodies by
the PregSure® BVD vaccine is due to antigen(s) derived
from bovine kidney cells that are described for propaga-
tion of the vaccine virus. As we could not obtain further
details about this cell line we assumed that it is derived
from Mabin-Darby bovine kidney (MDBK) cells (ATCC-
CCL22) that are most commonly applied for the propaga-
tion of BVDV. Surface proteins of MDBK cells were
labelled and used for immunoprecipitation. Sera from four
different groups of animals were tested for their reactivity
with biotinylated cell surface proteins of MDBK cells.
Group 1 consisted of sera of twelve dams from two differ-
ent farms, all of which had been vaccinated with Preg-
Sure® BVD and had at least one confirmed case of BNP in
gestation history (BNP-dam). All sera from this group pre-
cipitated antigens of approximately 44 kDa and 12 kDa
(reactivity of eight sera shown in Figure 1A). For these two
proteins only slight differences with regard to the signal
strength were observed. The signal intensity of both pro-
teins appeared to be connected, individuals with a strong
signal for the 44 kDa protein showed also a strong signal
intensity for the 12 kDa protein and vice versa. Group 2
consisted of eight dams from one farm without BNP his-
tory that had been vaccinated with a different BVD vac-
cine (Bovilis® BVD, Intervet). These sera did not show
apparent reactivity with cell surface proteins (Figure 1B)
except for two sera that led to weak signal with proteins of
apparent molecular weight of 44 and 12 kDa (Figure 1B,
lanes 5+7). As additional negative control eight sera of
dams that had neither been vaccinated against BVD, nor
had been infected with BVDV (Group 3), were included in
the experiment. No reactivity with the 44 kDa and 12 kDa
proteins from biotinylated MDBK cells was observed with
antibodies of these animals (Figure 1C).
As only a subset of PregSure® BVD vaccinated dams
give birth to BNP-calves, antibodies of non-BNP-dams
vaccinated with PregSure® BVD (Group 4) were ana-
lyzed with surface biotinylated MDBK cells using the
above mentioned methods. From four dams repeatedly
vaccinated with PregSure® BVD, sera of two animals
precipitated the 44 kDa and 12 kDa proteins observed
previously (Figure 1D, lanes 1+4; see discussion), the
other two showed no reactivity (Figure 1D, lanes 2+3).
To determine the glycosylation status of the recognized
proteins PNGase F digestion was performed on BNP-dam
serum precipitated MDBK cell surface proteins. For the
44 kDa protein a reduction of the apparent molecular
mass of approximately 4 kDa was observed (Figure 1E,
lane 2) compared to undigested protein (Figure 1E, lane 1)
revealing N-glycosylation of this protein. No mass shift
was detected for the 12 kDa protein.
Antibodies of BNP dams recognize 44 kDa and 12 kDa
cell surface antigens on primary leukocytes of susceptible
calves and non-BNP-dams
Surface biotinylated leukocyte samples from BNP-dams
(Figure 2, lane 2), from non-BNP-dams (vaccinated with
PregSure® BVD, lacking of antibodies against the 44 and
12 kDa protein) (Figure 2, lane 3), and from a BNP suscep-
tible calf [21] (Figure 2, lane 1) were precipitated with
serum from a BNP-dam. Antibodies of BNP-dam serum
led to the detection of antigens apparently of the same
molecular mass (44 kDa and 12 kDa) on leukocytes of the
susceptible calf and non-BNP-dams, respectively. No reac-
tivity or very weak reactivity of BNP-dam serum was
observed with specific proteins from leukocytes from a dif-
ferent BNP-dam. The results were reproduced with two
other sera from BNP-dams using the same leukocyte
preparations (from susceptible calf, BNP-dams and non-
BNP-dams) (data not shown).
Identification of MHC I and b-2-microglobulin by peptide
mass fingerprinting
For the identification of the detected antigens, 3 × 107
biotinylated MBDK cells were incubated with a strongly
reactive BNP-dam serum, and resulting immune com-
plexes were purified with immobilized protein-G. The
eluate was subjected to SDS-PAGE, and the gel was
stained with coomassie brilliant blue G-250. The discrete
protein bands occurring around 44 kDa and 12 kDa (Fig-
ure 3A) were excised, digested with trypsin and the
released peptides subjected to MALDI-TOF mass spec-
trometry. 16 peptides of the 44 kDa protein matched
with a sequence coverage of 49.2% to two cattle MHC
class I variants [EMBL:AAZ73457.1 (http://www.ebi.ac.
uk/ena/data/view/AAZ73457), EMBL:AAZ73463.1
(http://www.ebi.ac.uk/ena/data/view/AAZ73463)] (Figure
3B). According to the IPD database [29] these sequences
correlate to BoLA-N*01101 (genomic DNA: [EMBL:
DQ121184]) and BoLA-N*05001 (genomic DNA: [EMBL:
DQ121190]), respectively. Two peptide masses (997.6 Da
and 1127.6 Da) derived from the 12 kDa band, matched
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to tryptic peptides 103HVTLEQPR and 68SEQSDLSFSK,
respectively, of bovine b-2-microglobulin [EMBL:
AAI18353.1 (http://www.ebi.ac.uk/ena/data/view/
AAI18353)] yielding a coverage of 15.3%.
MHC I is a contaminant of the PregSure® BVD vaccine
If in fact the vaccine is responsible for the alloantibody
induction against MHC I, the respective molecule has to
be a constituent of the vaccine. To analyze its antigen
composition the proteinaceous components of the vac-
cine were precipitated using acetone and subjected to
immunoblot analyses. Using murine mAb against bovine
MHC I (IL-A88), the 44 kDa protein was easily detectable
in the PregSure® BVD vaccine (Figure 4, lane 1). The
same signal was observed with a lysate from MDBK cells
(Figure 4 lane 2) that was employed as a control. Further
to this IL-A88 was strongly reactive with the 44 kDa pro-
tein that was immunoprecipitated from MDBK cells
using a serum from a BNP-dam (Figure 4, lane 3). This
can be taken as independent evidence that the BNP sera
and IL-A88 react with the same antigen, MHC I.
Discussion
The key experiment for identification of bovine MHC I
as an antigen detected by alloreactive antibodies was the
labelling of cell surface proteins with biotin together
with immunoaffinity purification using mild conditions.
All sera from BNP-dams (n = 12) previously vaccinated
with PregSure® BVD reacted with apparently the same
44 kDa and 12 kDa antigens of MDBK cells (Figure 1A).
Figure 1 Reactivity of sera from different groups of animals with biotinylated MDBK lysate in immunoprecipitation. Figure 1A:
Reactivity of sera from eight BNP-dams (Group 1), which were previously vaccinated with PregSure® BVD, was tested with cell surface
biotinylated MDBK lysate. For all experiments gel electrophoresis was employed under non-reducing conditions to prevent a cleavage of the
biotin linker. Figure 1B: Eight sera of dams, which were vaccinated with a different inactivated BVD-vaccine (Bovilis® BVD, Intervet) (Group 2)
were tested for their reactivity with cell surface biotinylated MDBK lysate. Figure 1C: Eight sera of dams which were not vaccinated against BVD
(Group 3), and originated from farms free of BVD, were tested for their reactivity with cell surface biotinylated MDBK lysate. Figure 1D: Four sera
of dams vaccinated with PregSure® BVD previously but without known BNP case in their offspring history (non-BNP-dams) (Group 4) were tested
for alloantibodies recognizing protein species from cell surface biotinylated MDBK lysate (lane 1-4). Figure 1E: Deglycosylation of precipitate (from
Figure 1A) with PNGase F. Lane 1: native precipitate. Lane 2: PNGase F digested precipitate.
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In contrast sera from non vaccinated dams (n = 8,
Figure 1c) or dams vaccinated with a different BVD vac-
cine (n = 8, Figure 1B) showed no or only a very weak
reactivity. Additional cell surface antigens recognized by
individual sera cannot be excluded from participation in
BNP pathogenesis at this time.
For protein identification, alloantigens isolated by
immunoprecipitation from MDBK cells were subjected to
peptide mass fingerprinting analyses. The peptide mass
fingerprints covered 49.2% of the bovine MHC I
sequences (Figure 3B) of two variants of bovine MHC I,
and 15.3% of the mature bovine b-2-microglobulin
sequence (not shown). MHC I is a highly polymorphic,
N-glycosylated, membrane bound protein that is trans-
ported to the cell surface in non-covalent association
with b-2-microglobulin (MW: 12 kDa). MHC I molecules
are present on all nucleated cells, but the expression
levels are especially high on hematopoietic cells [30].
Functions of MHC I include the presentation of peptides
(8-10 amino acids) from endogenous antigens to CD8+
T-cells at the cell surface. Heterologous MHC I mole-
cules are involved in graft rejection [31]. According to
the IPD database [29] there are at least 61 different alleles
in cattle encoding MHC I. Six gene loci for MHC I are
uniformly located on chromosome 23 resulting in a max-
imum of 12 different alleles in each individual animal
[32]. In contrast, bovine b-2-microglobulin is invariable.
Using monoclonal antibody IL-A88 directed against
bovine MHC I a 44 kDa protein was detected in the
Figure 2 Reactivity of serum from a BNP-dam with leukocytes
from different animals. Immunoprecipitation was performed with
serum of a BNP-dam on cell surface biotinylated leukocytes from a
susceptible calf (lane 1), a different BNP-dam (lane 2) and a non-
BNP-dam, which was vaccinated with PregSure® BVD, but was
tested negative for MHC I alloantibodies (lane 3). The 44 kDa and 12
kDa protein (arrows) were only recognized in the susceptible calf
and the non-BNP-dam.
Figure 3 MALDI-TOF peptide mass fingerprinting analysis. Figure 3A: Coomassie brilliant blue G250 stained gel of BNP-dam serum
precipitated MDBK lysate. Bands of interest (44 kDa and 12 kDa, arrows) were excised and analyzed by MALDI-TOF peptide mass fingerprinting.
Figure 3B: MHC I [EMBL:AAZ73457.1 (http://www.ebi.ac.uk/ena/data/view/AAZ73457)] sequence coverage of detected peptides was 49.2% (blue
bars). Two peptide masses (997.6 Da; 1127.6 Da) derived from the 12 kDa band, matched to tryptic peptides 103HVTLEQPR and 68SEQSDLSFSK of
bovine b-2-microglobulin [EMBL:AAI18353.1 (http://www.ebi.ac.uk/ena/data/view/AAI18353)].
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PregSure® BVD vaccine (Figure 4, lane 1). IL-A88 and
BNP-dam sera both recognize the 44 kDa antigen from
MBDK cells (Figure 4, lane 3).
The BNP syndrome has in most cases been reported
for offspring of dams that received PregSure® BVD vac-
cination. Interestingly BNP syndrome occurred only in a
relatively small number of PregSure® BVD vaccinated
animals [20]. This indicates that factors in addition to
the vaccine are relevant for the establishment of BNP.
All tested BNP-dam sera recognized MHC I. From the
four tested non-BNP-dams two sera did not show a
reactivity with MHC I, although these dams were vacci-
nated with PregSure® BVD (Figure 1D, lane 2 and 3).
Whereas the two remaining sera of non-BNP-dams dis-
played clear reactivity with MHC I (Figure 1D, lane 1
and 4), but offspring of these dams was healthy in
regard to BNP. Are these observations compatible with
a role of antibodies to MHC I in BNP pathogenesis?
PregSure® BVD is produced by propagation of BVDV
strain 5960 on bovine kidney cells and thus MHC I
represents a contaminant. Whether the vaccine derived
MHC I is antigenic in vaccinated dams must depend on
the MHC I allotype constellation of the individual ani-
mal. If a vaccinated dam shares MHC I allotypes present
in the PregSure® BVD vaccine no immune response will
ensue and consequently no BNP will occur. This is
probably true for two PregSure® BVD vaccinated ani-
mals that did not recognize MHC I from MDBK cells.
Further evidence for this assumption is the presence of
antigenetic MHC I variant(s) of BNP alloantibodies on
non-BNP-dam leukocytes (Figure 2, lane 3). If a dam
differs in its allotype repertoire it recognizes MHC I
from the vaccine as foreign antigen and an immune
response will be mounted. This is the case for all BNP-
dams of this study as they all show reactivity with MHC
I from MDBK cells (Figure 1A) and do not react with
MHC I epitope(s) of leukocytes from other BNP-dams
(Figure 2, lane 2). The occurrence of BNP is thus
restricted to calves that share common MHC I epitope
(s) with the PregSure® BVD vaccine and originate from
dams lacking this epitope(s). The MHC I allotype that
renders calves susceptible (or unsusceptible) has to be
of paternal origin. Calves carrying a paternally trans-
mitted MHC I variant similar to that of the PregSure®
BVD vaccine will be targeted by maternal alloantibodies.
Binding of the alloantibodies will lead to complement
dependent lysis and/or cytophagocytosis [20], preferen-
tially of cells expressing high levels of antigen. If the
transmitted paternal allotype differs from MHC I in
PregSure® BVD no binding of the maternal alloantibo-
dies to hematopoietic cells will occur and the calf will
be unaffected. We therefore postulate that BNP occur-
rence is restricted to certain combinations of MHC I
allotypes (Figure 5). It is currently not possible to pre-
dict whether the BNP susceptibility is conferred by a
single or multiple MHC I alleles and whether these are
rare or abundant in the population. Future studies will
therefore aim at the determination of alloantigenic
MHC I variants and their distribution in the cattle
population. Cloning and expression of the respective
MHC I genes will be required to define reactive MHC I
variants. Using these approaches mapping of alloanti-
body specific epitopes on MHC I will be addressed in
future experiments.
In cases of BNP only hematopoietic and bone marrow
cells are clearly affected. However, MHC I is expressed
on every nucleated cell. Why are other cells not
destroyed? One possible explanation is the density of
MHC I on the surface of cells, which is known to be high
on hematopoietic cells [30]. Future investigations will
determine amount and surface localization of MHC I in
different cell populations particularly endothelial and
epithelial cells.
According to our model alloantibodies against MHC I
are responsible for the occurrence of BNP. It is generally
Figure 4 Detection of MHC I in PregSure® BVD vaccine. Western
blot analysis with the monoclonal antibody IL-A88 against bovine MHC
I was applied to the PregSure® BVD vaccine (lane 1). The antibody was
further employed on native MDBK cell lysate (lane 2) and a precipitate
from MDBK cells obtained with serum of a BNP-dam (lane 3).
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assumed that BNP is a severe and in most cases lethal
disease, with only a few calves surviving [1,5-7]. How-
ever recently a single herd with some BNP cases was
thoroughly investigated with regard to blood parameters
[33]. It turned out that a significant number of calves
without clinical signs of BNP showed alterations in at
least two of the three blood cell lineages. This observa-
tion leads to the assumption that the occurrence of BNP
is probably dependent on the amount of alloantibodies
against MHC I taken up with the colostrum. A low
amount of such alloantibodies does probably not lead to
clinical signs (as those are not known from the offspring
of the two animals of Group 2, whose serum also
showed a weak reaction with MHC I). Factors which
could influence BNP occurrence are (i) the amount of
colostrum taken up in the first 36 h of life, which differs
from calf to calf [34], (ii) the individual titer of MHC I
alloantibodies in a dam’s colostrum arising from the
number of boosts dams got with the PregSure® BVD
vaccine and the time point after vaccination. Occurrence
Figure 5 Model of the BNP-etiology. Dams vaccinated with PregSure® BVD which carry the MHC I variant(s) of the vaccine on their cells (top
left dam, MHC I colored in red) do not produce MHC I alloantibodies and their offspring does not develop BNP. If the MHC I variant(s) on the
cells differ from MHC I variant(s) from the vaccine (top right dam, MHC I colored in blue) alloantibody production is induced. In this case the
development of BNP depends on hereditary transmission of paternal MHC I variants. If the paternal MHC I variants are not recognized by the
alloantibodies no BNP will occur (bottom left calf). BNP syndrome only appears if the paternal MHC I variants match with the MHC I variants
present in the PregSure® BVD vaccine (bottom right calf). Calves of both genders develop BNP equally as gene loci for MHC I are located on an
autosome (chromosome 23).
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presumably also depends on (iii) the affinity of alloanti-
bodies to the MHC I variants of individual calves
allotype.
Interestingly, a rare disease termed “neonatal alloim-
mune thrombocytopenia” (NAIT) occurring in human
infants shows resemblance with clinical symptoms of
BNP. The NAIT syndrome is caused by diaplacental
transmission of maternal antibodies that are directed
against paternal alloantigens on hematopoietic cells.
While alloantibodies in most NAIT cases are directed
against human platelet antigen (HPA) [35], some cases of
NAIT have been linked to human leukocyte antigens
(HLA), the human homologue to cattle MHC I (BoLA)
[36]. In humans, antibodies can freely cross the placenta
barrier so that alloantibodies can affect the fetus in utero.
This is different in ruminants, because the placenta
epitheliochorials is impermeable to immunoglobulins
and maternal antibodies including BNP-alloantibodies
are transmitted to the newborn exclusively in the first
hours of life by uptake of colostral milk [21].
In the context of PregSure® BVD the immune enhancing
impact of the adjuvant Quil A has to be considered. Pre-
vious studies have shown, that PregSure® BVD vaccination
led to a robust immunity against BVD correlating with the
induction of very high neutralizing antibody titers [37,38].
Therefore, it is conceivable that this special adjuvant
induces a disproportionate immune response not only
against viral antigens, but also against cellular alloantigens
and may thereby be of pivotal importance in BNP
induction.
The observation that the presence of MHC I in a vac-
cine probably causes a lethal disease in calves is relevant
for inactivated vaccines in general. The use of a homolo-
gous production system (i.e. bovine cells for a bovine vac-
cine) bears potential risks for alloantibody induction and
should therefore be avoided.
In conclusion, we have provided evidence that PregSure®
BVD vaccination leads to the induction of alloantibodies
against MHC I which are probably linked to the pathogen-
esis of BNP. While it cannot be excluded that other alloan-
tigens contribute to the development of BNP, MHC I is an
excellent candidate. Future studies will include the repro-
duction of the disease by vaccination of purified compo-
nents such as MHC I in combination with Quil A.
Acknowledgements
We gratefully acknowledge the support of Rolf Bauerfeind, Simone
Schillinger and Julia Francke, Justus-Liebig-Universiy, Giessen.
This work was financially supported by the German Federal Ministry ofFood,
Agriculture and Consumer Protection (BMELV) through the FederalOffice for
Agriculture and Food (BLE), grant number 2809HS025.
Author details
1Institute of Virology, Faculty of Veterinary Medicine, Justus-Liebig-University
Giessen, Germany. 2Institute of Biochemistry, Justus-Liebig-University Giessen,
Germany. 3Clinic for Ruminants, Faculty of Veterinary Medicine, Justus-Liebig-
University Giessen, Germany.
Authors’ contributions
FD, BL and TR carried out the experiments, participated in the data
collection and analysis, and prepared the manuscript. CMR, EW, KD and HJT
participated in the design of the study, draft of the manuscript and
manuscript revision. GL participated in data collection (MALDI-MS) and data
analysis. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 June 2011 Accepted: 30 August 2011
Published: 30 August 2011
References
1. Friedrich A, Rademacher G, Weber B, Kappe E, Carlin A, Assad A, Sauter-
Louis C, Hafner-Marx A, Büttner M, Böttcher J, Klee W: Gehäuftes Auftreten
von hämorrhagischer Diathese infolge Knochenmarkschädigung bei
jungen Kälbern. Tierärztl Umschau 2009, 64:423-431, in German.
2. Buiatrie SFdB: Abstracts Haemorrrhagic Diathesis in Calves. In Proceedings
of the Satellite Symposium “Haemorrrhagic Diathesis in Calves”. Edited by:
Klee W. Société Francaise de Buiatrie; 2009:1-29, Marseille.
3. Armengol R, Ponté D, de Prado A, Sierra M, Casa M, de las Heras M,
Uixera A, García-Jalón J: Síndrome dela diátesis hemorrágica del ternero
(pancitopenia neonatal bovina) en Espana. Boletín de anembe 2010,
85:28-31, (in Spanish).
4. Friedrich A, Büttner M, Rademacher G, Klee W, Weber BK, Müller M, Carlin A,
Assad A, Hafner-Marx A, Sauter-Louis CM: Ingestion of colostrum from
specific cows induces Bovine Neonatal Pancytopenia (BNP) in some
calves. BMC Vet Res 2011, 7:10.
5. Bell C, Scott P, Penny C: Ten cases of “Bleeding Calf Syndrome” in a
Scottish beef herd: Clinical signs, haematology and attempted
treatment. In Proceedings of the Satellite Symposium “Haemorrrhagic
Diathesis in Calves”. Edited by: Klee W. Toulouse: Société Francaise de
Buiatrie; 2009:17, Marseille.
6. Bell C, Scott P, Penny C: Ten cases of “Bleeding Calf Syndrome” in a
Scottish beef herd: post-mortem findings. In Proceedings of the Satellite
Symposium “Haemorrrhagic Diathesis in Calves”. Edited by: Klee W. Toulouse:
Société Francaise de Buiatrie; 2009:21, Marseille.
7. Corbiere F, Foucras G, Lacroux C, Meyer G, Schelcher F: Haemorrhagic
diathesis syndrome: clinical and epidemiological findings of 48
suspected cases in France, 2007-2009. In Proceedings of the Satellite
Symposium “Haemorrrhagic Diathesis in Calves”. Edited by: Klee W. Toulouse:
Société Francaise de Buiatrie; 2009:11-13, Marseille.
8. Pardon B, Steukers L, Dierick J, Ducatelle R, Saey V, Maes S, Vercauteren G,
De Clercq K, Callens J, De Bleecker K, Deprez P: Haemorrhagic diathesis in
neonatal calves: an emerging syndrome in Europe. Transbound Emerg Dis
2010, 57:135-146.
9. Kappe EC, Halami MY, Schade B, Alex M, Hoffmann D, Gangl A, Meyer K,
Dekant W, Schwarz BA, Johne R, Buitkamp J, Böttcher J, Müller H: Bone
marrow depletion with haemorrhagic diathesis in calves in Germany:
characterization of the disease and preliminary investigations on its
aetiology. Berl Munch Tierarztl Wochenschr 2010, 123:31-41.
10. Willoughby K, Gilray J, Maley M, Dastjerdi A, Steinbach F, Banks M,
Scholes S, Howie F, Holliman A, Baird P, McKillen J: Lack of evidence for
circovirus involvement in bovine neonatal pancytopenia. Vet Rec 2010,
166:436-437.
11. Krappmann K, Weikard R, Gerst S, Wolf C, Kuhn C: A genetic predisposition
for bovine neonatal pancytopenia is not due to mutations in
coagulation factor XI. Vet J .
12. Ballingall KT, Nath M, Holliman A, Laming E, Steele P, Willoughby K: Lack of
evidence for an association between MHC diversity and the
development of bovine neonatal pancytopenia in Holstein dairy cattle.
Vet Immunol Immunopathol 2011, 141:128-132.
13. Doll K, Wenzel L, König M: Krankheitsverlauf bei Kälbern mit
hämorrhagischer Diathese. Congr Proc 2nd Meeting of the “Deutsche
Buiatrische Gesellschaft”, Berlin 2010, 20-23.
14. Bauer N, Wenzel L, Moritz A, Doll K: Entwicklung der Blutbild- und
Knochenmarksbefunde bei Kälbern mit hämorrhagischer Diathese. Cong
Deutskens et al. Veterinary Research 2011, 42:97
http://www.veterinaryresearch.org/content/42/1/97
Page 9 of 10
Proc 2nd meeting of the German Buiatrics Association; DVG-Service GmbH;
Berlin 2008, 23-29.
15. Summary of Product Characteristics, PregSure BVD. [http://www.vmd.
defra.gov.uk/ProductInformationdatabase/].
16. Lendemans DG, Myschik J, Hook S, Rades T: Cationic cage-like complexes
formed by DC-cholesterol, Quil-A, and phospholipid. J Pharm Sci 2005,
94:1794-1807.
17. Pham HL, Ross BP, McGeary RP, Shaw PN, Hewavitharana AK, Davies NM:
Saponins from Quillaja saponaria Molina: isolation, characterization and
ability to form immuno stimulatory complexes (ISCOMs). Curr Drug Deliv
2006, 3:389-397.
18. Sjolander A, van’t Land B, Lovgren Bengtsson K: Iscoms containing purified
Quillaja saponins upregulate both Th1-like and Th2-like immune
responses. Cell Immunol 1997, 177:69-76.
19. Platt R, Coutu C, Meinert T, Roth JA: Humoral and T cell-mediated
immune responses to bivalent killed bovine viral diarrhea virus vaccine
in beef cattle. Vet Immunol Immunopathol 2008, 122:8-15.
20. Bastian M, Holsteg M, Hanke-Robinson H, Duchow K, Cussler K: Bovine
Neonatal Pancytopenia: Is this alloimmune syndrome caused by
vaccine-induced alloreactive antibodies? Vaccine 2011, 29:5267-5275.
21. Bridger PS, Bauerfeind R, Wenzel L, Bauer N, Menge C, Thiel HJ,
Reinacher M, Doll K: Detection of colostrum-derived alloantibodies in
calves with bovine neonatal pancytopenia. Vet Immunol Immunopathol
2011, 141:1-10.
22. Pardon B, Stuyven E, Stuyvaert S, Hostens M, Dewulf J, Goddeeris BM,
Cox E, Deprez P: Sera from dams of calves with bovine neonatal
pancytopenia contain alloimmune antibodies directed against calf
leukocytes. Vet Immunol Immunopathol 2011, 141:293-300.
23. Pfizer, Pfizer animal health stops sale of cattle BVD vaccine in the EU.
2010 [http://www.pfizerah.co.uk/sites/sante-animale/UK-English/News/
Pages/Pregsure_BVD_press_release.aspx].
24. Luther DG, Cox HU, Nelson WO: Screening for neonatal isohemolytic
anemia in calves. Am J Vet Res 1985, 46:1078-1079.
25. Osterhoff DR, de Vos AJ: Isoimmune blood group antibodies in cattle
after the use of a blood vaccine. J S Afr Vet Assoc 1977, 48:137-139.
26. Stormont C: Neonatal isoerythrolysis in domestic animals: a comparative
review. Adv Vet Sci Comp Med 1975, 19:23-45.
27. Toye PG, MacHugh ND, Bensaid AM, Alberti S, Teale AJ, Morrison WI:
Transfection into mouse L cells of genes encoding two serologically and
functionally distinct bovine class I MHC molecules from a MHC-
homozygous animal: evidence for a second class I locus in cattle.
Immunology 1990, 70:20-26.
28. Schagger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide
gel electrophoresis for the separation of proteins in the range from 1 to
100 kDa. Anal Biochem 1987, 166:368-379.
29. Robinson J, Mistry K, McWilliam H, Lopez R, Marsh SG: IPD–the Immuno
Polymorphism Database. Nucleic Acids Res 2010, 38:863-869 [http://www.
ebi.ac.uk/ipd/mhc/bola].
30. Agrawal S, Kishore MC: MHC class I gene expression and regulation.
J Hematother Stem Cell Res 2000, 9:795-812.
31. Clatworthy MR, Espeli M, Torpey N, Smith KGC: The generation and
maintenance of serum alloantibody. Curr Opin Immunol 2010, 22:669-681.
32. Birch J, Codner G, Guzman E, Ellis SA: Genomic location and
characterisation of nonclassical MHC class I genes in cattle.
Immunogenetics 2008, 60:267-273.
33. Witt K, Weber CN, Meyer J, Buchheit-Renko S, Müller KE: Haematological
analysis of calves with bovine neonatal pancytopenia. Vet Rec .
34. Vasseur E, Rushen J, de Passille AM: Does a calf’s motivation to ingest
colostrum depend on time since birth, calf vigor, or provision of heat?
J Dairy Sci 2009, 92:3915-3921.
35. Kaplan C: Foetal and neonatal alloimmune thrombocytopaenia. Orphanet
J Rare Dis 2006, 1:39.
36. Gramatges MM, Fani P, Nadeau K, Pereira S, Jeng MR: Neonatal
alloimmune thrombocytopenia and neutropenia associated with
maternal human leukocyte antigen antibodies. Pediatr Blood Cancer 2009,
53:97-99.
37. Raue R, Harmeyer SS, Nanjiani IA: Antibody responses to inactivated
vaccines and natural infection in cattle using bovine viral diarrhoea
virus ELISA kits: assessment of potential to differentiate infected and
vaccinated animals. Vet J 2011, 187:330-334.
38. Salt S, Antonis A, Peters A, Brune A, Jahnecke S, Traeder W: PregSure® BVD
- eine neue inaktivierte BVD-Vakzine. Breite Kreuzneutralisation von
europäischen BVDV-Typ-1-und-Typ-2-Stämmen und signifikante
Verbesserung der Fertilität nach Testinfektionen. Tierarztl Prax Ausg G
Grosstiere Nutztiere 2004, 32(4):91-195, in German.
doi:10.1186/1297-9716-42-97
Cite this article as: Deutskens et al.: Vaccine-induced antibodies linked
to bovine neonatal pancytopenia (BNP) recognize cattle major
histocompatibility complex class I (MHC I). Veterinary Research 2011 42:97.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Deutskens et al. Veterinary Research 2011, 42:97
http://www.veterinaryresearch.org/content/42/1/97
Page 10 of 10
